RUNX1 and non-Hodgkin lymphoma: Here, we predicted that RUNX1 may be an effective target in Non-Hodgkin Lymphoma, and that the residues of RUNX1 that are involved in interacting with Ibrutinib are also in proximity to the DNA binding interface of RUNX1.